You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser.
Administrator
Staff member
-
cafead   Jan 31, 2025 at 11:32: AM
Administrator
Staff member
via Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome.
article source